PMID- 21208168
OWN - NLM
STAT- MEDLINE
DCOM- 20110613
LR  - 20191111
IS  - 1874-4745 (Electronic)
IS  - 1874-4737 (Linking)
VI  - 3
IP  - 4
DP  - 2010 Dec
TI  - Recent topics on pharmacotherapy for amphetamine-type stimulants abuse and 
      dependence.
PG  - 222-38
AB  - Abuse of amphetamine-type stimulants (ATS), including amphetamine, 
      methamphetamine (METH), and 3,4-methylenedioxymethamphetamine (MDMA; ecstasy), 
      has become a major public health problem worldwide. Use of these stimulants has 
      significant psychiatric and medical consequences, including psychosis, 
      dependence, overdose, and death. METH abuse in particular is an extremely serious 
      and growing problem in many countries. The development of treatments for 
      METH-related problems is particularly critical for users who experience 
      persistent psychosis, pregnant women and women with children, gay and bisexual 
      men, and users involved in the criminal justice system. However, there are 
      currently no pharmacological treatments for the wide range of symptoms associated 
      with METH-related problems. One of the reasons for this problem is that our 
      knowledge of the cellular and molecular mechanisms underlying the development of 
      METH-induced psychosis and dependence is limited. In this article, we review 
      recent reports on potential pharmacotherapies (naltrexone, minocycline, 
      antioxidants, immunotherapy, and dopaminergic, serotonergic, cholinergic, and 
      GABAergic agents) for the treatment of ATS abusers.
FAU - Chen, Hongxian
AU  - Chen H
AD  - Division of Clinical Neuroscience, Chiba University Center for Forensic Mental 
      Health, Japan.
FAU - Wu, Jin
AU  - Wu J
FAU - Zhang, Jichun
AU  - Zhang J
FAU - Hashimoto, Kenji
AU  - Hashimoto K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Drug Abuse Rev
JT  - Current drug abuse reviews
JID - 101468123
RN  - 0 (Antioxidants)
RN  - 0 (Psychotropic Drugs)
SB  - IM
MH  - Amphetamine-Related Disorders/*drug therapy
MH  - Antioxidants/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Molecular Structure
MH  - Psychotropic Drugs/*therapeutic use
MH  - Synaptic Transmission/drug effects
EDAT- 2011/01/07 06:00
MHDA- 2011/06/15 06:00
CRDT- 2011/01/07 06:00
PHST- 2010/07/02 00:00 [received]
PHST- 2010/11/01 00:00 [accepted]
PHST- 2011/01/07 06:00 [entrez]
PHST- 2011/01/07 06:00 [pubmed]
PHST- 2011/06/15 06:00 [medline]
AID - CDAR ABS-23 [pii]
AID - 10.2174/1874473711003040222 [doi]
PST - ppublish
SO  - Curr Drug Abuse Rev. 2010 Dec;3(4):222-38. doi: 10.2174/1874473711003040222.